This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considere

Full Press Release Details

A Leading Immunotherapy Biotech Company

Broadest Late-Stage Clinical Platform of Antibody Cytokine Fusion Proteins, Albumin-Linked Chemo-Immunomodulators, Vaccine Vectors and Natural Killer cells NASDAQ:IBRX Exhibit 99.1

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually

identified by the use of words such as "anticipates," "believes," "continues", "could", "estimates," "expects," "intends," "may," "plans,"

"potential", "predicts", "projects," "seeks," "should," "will," and variations of such words or similar expressions. These forward-looking statements are neither forecasts,

promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect

to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse

effects or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger , (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger,

(iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and

value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing

and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain

clinical trial milestones and/or ImmunityBio's operations or operating expenses. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the

Company's Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on March 10, 2021 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at www.sec.gov.

ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press

release, except to the extent required by law. Forward Looking Statements

ImmunityBio: A Leading Immunotherapy

Company 17 First in Human Immunotherapy Molecules and cells 40 Phase I / II / III Clinical Trials 1,800+ Patients Studied 25 Phase II / III Clinical Trials 400,000 Square Feet of Manufacturing and R&D Facilities 3 Trillion Over 3 Trillion

Natural Killer Cells Manufactured to Date > Antibody Cytokine Fusion Proteins A Leading Immunotherapy Platform in Oncology & Infectious Diseases Chemo Immuno Modulators Vaccine Technologies Natural Killer Cells NASDAQ: IBRX 2035+ Worldwide

Patents Extending to 2035 and Beyond

Highly Experienced Management Team with

Proven Track Record Patrick Soon-Shiong, MD Executive Chairman David Sachs, MBA Chief Financial Officer Rich Adcock, MBA Chief Executive Officer Bobby Reddy, MD Chief Medical Officer Lennie Sender, MD Chief Operating Officer Fabio Benedetti, MD

Chief Strategy Officer Shahrooz Rabizadeh, PhD Chief Scientific Officer Fusion Protein & Neoepitope Kayvan Niazi, PhD Chief Science Officer Immunology and Vaccinology Elizabeth Gabitzsch Vice President, Vaccines Sarah Singleton Chief

Communications Officer Hans Klingemann, MD, PhD Chief Scientific Officer Cellular Therapy Manju Saxena, PhD Vice President, Product Dev Cell Therapy Program Sylvain Roy Vice President, Manufacturing Barry Simon, MD Chief Corporate Affairs

A Leading Immunotherapy Platform in

Oncology and Infectious Diseases Aldoxorubicin Anktiva (N-803) Adenovirus (hAd5) Antibody Cytokine Fusion Proteins Activating NK & T Cells Albumin-Bound Immuno-Modulators Tumoricidal Macrophages Vaccine Technologies Memory T Cells Mechanism of

Action Core Modalities Lead pH- Sensitive Hydrazine Linker Albumin-binding site Cytokine Cytokine Fusion Antibody (IgG1) Natural Killer (NK) Natural Killer Off-the-Shelf NK Cells Autologous Memory ceNK hAd5

ImmunityBio's Immunotherapy

Platform: Antibody Cytokine Fusion Proteins Anktiva (N-803) Antibody Cytokine Fusion Proteins Activating NK & T Cells Mechanism of Action Core Modalities Lead Cytokine Cytokine Fusion Antibody (IgG1)

ImmunityBio's Immunotherapy

Platform: Albumin-Bound Immuno-Modulators Aldoxorubicin Albumin-Bound Immuno-Modulators Tumoricidal Macrophages Mechanism of Action Core Modalities Lead pH- Sensitive Hydrazine Linker Albumin-binding site

ImmunityBio's Immunotherapy

Platform: Vaccine Technologies Adenovirus (hAd5) Vaccine Technologies Memory T Cells Mechanism of Action Core Modalities Lead hAd5

ImmunityBio's Immunotherapy

Platform: Natural Killer Cell Therapy Mechanism of Action Core Modalities Lead Natural Killer (NK) Natural Killer Off-the-Shelf NK Cells Autologous Memory ceNK 1 2 3